Strengthen cardiomyopathy drug therapy on NT-proBNP and cardiax chamber in patients with uremic cardiomyopathy

Objective To investigate the clinical effect of strengthen cardiomyopathy therapy on uremic cardiomyopathy with the change of the NT-proBNP and cardiac chamber.Methods 100 patients of uremic cardiomyopathy were divided into strengthen treatment group and conventional treatment group randomly,each group had 50 patients.In conventional treatment group,the hemodialysis was applied,and in strengthen treatment group,the drug therapy was applied on the basis of hemodialysis. The expression of NT-proBNP,the change of cardiac chamber and ejection fraction were detected and compared in both two groups.Results The result showed that the cardiac function was improved obviously in strengthen treatment group than that of in conventional treatment group,with the decline of the expression of NT-proBNP significantly(P0.05).The cardiac chamber size contraction and cardiac ejection fraction increase rate were improved significantly in strengthen treatment group than those of conventional treatment group(P0.05).The total effective rate was higher in strengthen treatment group (88.0%) than that of conventional treatment group(72.7%,P0.05).And no obvious adverse reactions was observed in both two groups.Conclusion It proved that adding the neuroendocrine medicine to the therapy of the patients with uremic myocardiopathy could improve the patients'cardiac function obviously,enhance the life quality and increase the life span.